Incepta Vaccine Ltd has operationalized an indigenous, fully integrated bulk facility that can manufacture both bacterial and viral bulk antigen independently.
The facility expects to produce bulk antigens for a range of vaccines that include a 13-valent pneumococcal conjugate vaccine and 4-valent human papilloma virus (HPV) vaccine. Those for hepatitis B,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?